3 citations
,
August 2024 in “Cureus” Upadacitinib may cause hair loss.
April 2016 in “Actas Dermo-Sifiliográficas” The document concludes that a unique target-like hair regrowth pattern in alopecia areata may be more common than thought and should be properly identified.
8 citations
,
May 2023 in “Cureus” Secukinumab for psoriasis may cause hair loss.
February 2025 in “PubMed” Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.
85 citations
,
October 2012 in “Dermatologic Clinics” Alopecia Areata is an autoimmune condition often starting before age 20, with varied treatment success and a need for personalized treatment plans.
October 2022 in “The Egyptian Journal of Hospital Medicine” Topical corticosteroids are the preferred first treatment for children with Alopecia Areata.
36 citations
,
May 2011 in “Dermatologic therapy” No treatments fully cure or prevent alopecia areata; some help but have side effects or need more research.
1 citations
,
September 2023 in “Dermatology and Therapy” Baricitinib helps improve hair growth in severe alopecia, with better results in less severe cases and higher doses working faster.
24 citations
,
January 2017 in “Pediatric dermatology” 1% anthralin ointment is effective and safe for treating severe alopecia areata in children.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” JAK inhibitors can help regrow hair in alopecia areata but have potential long-term risks and require careful monitoring.
17 citations
,
January 2019 in “Dermatologic Therapy” Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
55 citations
,
October 2019 in “Dermatology and therapy” Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.
36 citations
,
December 2015 in “Drugs” New treatments for a chronic skin condition show promise, but individualized plans are crucial due to varying responses.
8 citations
,
October 2022 in “Dermatology practical & conceptual” Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
4 citations
,
June 2025 in “Frontiers in Immunology” BAFF-targeted therapies can reduce autoimmune disease activity, but more research is needed for precise treatments.
1 citations
,
January 2019 in “Springer eBooks” Hidradenitis Suppurativa is a chronic skin condition best treated early with surgery for better outcomes and less recurrence.
14 citations
,
January 2017 in “Skin appendage disorders” Simvastatin/ezetimibe did not effectively treat severe alopecia areata and caused side effects in some patients.
5 citations
,
May 2017 in “Current Opinion in Pediatrics” Hormonal therapies are safe and effective for treating acne in female adolescents, with specific treatments for those with endocrine disorders.
4 citations
,
January 2018 in “Cancer treatment and research” The document concludes that systemic therapy is becoming more important in treating head and neck cancer, with new treatments showing promise.
April 2026 in “Dermatology and Therapy” TNFα inhibitors are effective and well-tolerated for treating severe scalp cellulitis.
July 2025 in “Revista Eletrônica Acervo Científico” Hydroxychloroquine is most effective for scarring alopecias, especially when combined with other treatments.
25 citations
,
March 2021 in “Australasian Journal of Dermatology” Ustekinumab successfully treated a man's resistant skin condition when other treatments failed.
2 citations
,
February 2023 in “Actas Dermo-Sifiliográficas” Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.
7 citations
,
November 2021 in “JAAD Case Reports” Mogamulizumab can cause hair loss and skin rashes.
Oral betamethasone mini-pulses effectively treat moderate to severe alopecia areata with manageable side effects.
Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.
January 2024 in “Case Reports in Dermatological Medicine” Baricitinib may effectively treat nail changes in alopecia areata.
37 citations
,
October 2014 in “JAMA dermatology” A woman with severe hair loss was successfully treated with the drug adalimumab.
December 2025 in “Medicine” Glutamine may protect against alopecia areata, while certain cholesterol and glucose levels may increase risk.
13 citations
,
February 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.